United Therapeutics (UTHR) traded lower on Wednesday, April 1, 2026, down roughly 3% to around $573, after opening near $597 and sliding to the low $571 area in intraday action. The move looks driven less by a fresh company announcement and more by post-catalyst repositioning following a strong March tape.

The stock had multiple bullish catalysts in March, including a newly authorized $2 billion repurchase program and a $1.5 billion accelerated share repurchase structure with Citi. With UTHR sitting near recent highs after that sequence of headlines, today’s downside action fits a “sell the strength” pattern as traders take profits. Adding to the near-term overhang, recent insider transactions tied to 10b5-1 selling plans were disclosed for senior leadership (including CEO and CFO), which can amplify caution in a stock that has rallied sharply.

In early March, United Therapeutics reported a strong Phase 3 ADVANCE OUTCOMES result for ralinepag, including a 55% reduction in risk of clinical worsening versus placebo, and reiterated plans to submit an NDA in the second half of 2026. Later in March, the company also highlighted TETON-2 Phase 3 results for nebulized Tyvaso in IPF with publication in a leading medical journal and pointed to expectations for TETON-1 results soon, supporting a potential label expansion pathway. Those developments helped re-rate expectations, leaving the stock vulnerable to a pullback without a new incremental positive catalyst on April 1.

Near-term, investors will track any additional Form 4 filings, updates on the ASR timing and share deliveries, and the next key clinical catalysts—especially the timing and details of the upcoming TETON-1 readout and steps toward U.S. filings for ralinepag and the IPF opportunity. If no negative fundamental news emerges, traders will likely treat the current weakness as a consolidation phase after March’s catalyst-driven move.